Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study

CONCLUSIONS: In current practice in France, the rate of subcutaneous abatacept persistence at 2 years was comparable with that of the intravenous form. Treatment persistence was higher when abatacept was used as first-line versus later-line biologic therapy.PMID:38436358 | DOI:10.55563/clinexprheumatol/ddx0fz

Source: Clinical and Experimental Rheumatology - March 4, 2024 Category: Rheumatology Authors: Ren é-Marc Flipo Arnaud Constantin Philippe Goupille M élanie Chartier Ana ël Ohayon Xavier Mariette Source Type: research